Detalhe da pesquisa
1.
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
Blood
; 132(1): 49-58, 2018 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29666118
2.
Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice.
Intern Med J
; 47(5): 542-548, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-27753208
3.
Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.
Am J Hematol
; 91(4): 410-5, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26799234
4.
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Lancet
; 377(9759): 42-51, 2011 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21176949
5.
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.
Clin Lymphoma Myeloma Leuk
; 20(8): 509-518, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32482541
6.
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
Leukemia
; 34(7): 1840-1852, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32024950
7.
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.
J Clin Oncol
; 37(31): 2815-2824, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31339826